Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naive MPTP-lesioned common marmosets (Callithrix jacchus)
Autore:
Maratos, EC; Jackson, MJ; Pearce, RKB; Jenner, P;
Indirizzi:
Univ London Kings Coll, Guys Kings & St Thomas Sch Biomed Sci, Neurodegenerat Dis Res Ctr, London SE1 1UL, England Univ London Kings Coll London England SE1 1UL r, London SE1 1UL, England
Titolo Testata:
MOVEMENT DISORDERS
fascicolo: 4, volume: 16, anno: 2001,
pagine: 631 - 641
SICI:
0885-3185(200107)16:4<631:AAADRO>2.0.ZU;2-W
Fonte:
ISI
Lingua:
ENG
Soggetto:
EARLY PARKINSONS-DISEASE; LEVODOPA-INDUCED DYSKINESIA; AGONIST-INDUCED DYSKINESIA; 6-MONTH INTERIM-REPORT; MOTOR COMPLICATIONS; DOUBLE-BLIND; FOLLOW-UP; PATHOPHYSIOLOGICAL MECHANISMS; BROMOCRIPTINE THERAPY; MONKEYS;
Keywords:
ropinirole; L-DOPA; dyskinesia; MPTP; Parkinson's disease;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
59
Recensione:
Indirizzi per estratti:
Indirizzo: Jenner, P Univ London Kings Coll, Guys Kings & St Thomas Sch Biomed Sci, Neurodegenerat Dis Res Ctr, Hodgkin Bldg,Guys Campus, London SE1 1UL, England Univ London Kings Coll Hodgkin Bldg,Guys Campus London England SE1 1UL
Citazione:
E.C. Maratos et al., "Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naive MPTP-lesioned common marmosets (Callithrix jacchus)", MOVEMENT D, 16(4), 2001, pp. 631-641

Abstract

De novo administration of long-acting dopamine agonists, such as ropinirole, to patients with Parkinson's disease or to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated subhuman primates produces a lower incidenceof dyskinesia than occurs with levodopa (L-DOPA). This study compares the intensity of dyskinesia produced by combinations of L-DOPA and ropinirole and by these drugs alone, using the MPTP-treated common marmoset model of Parkinson's disease. The objective is to determine the optimum therapeutic strategy for the long-term control of Parkinson's disease with a minimal riskof dyskinesia. MPTP-treated marmosets received either L-DOPA alone, ropinirole alone, or one of two combinations of these drugs (either L-DOPA dominant or ropinirole dominant) daily for 28 days in doses titrated to produce a similar improvement in disability and increase in locomotion. In the group receiving L-DOPA alone, there was a trend for peak dose locomotor activity to increase and the duration of drug effect to decline over the period of the study. L-DOPA alone induced marked dyskinesia over the period of treatment, in contrast to ropinirole which produced a low intensity of involuntary movements. The L-DOPA dominant combination initially produced little dyskinesia, but this became increasingly intense as the study progressed. In contrast, the ropinirole dominant combination produced no greater intensity of dyskinesia than was produced by ropinirole alone. These data suggest that in early Parkinson's disease, the use of ropinirole alone or in combination with a low-dose L-DOPA might delay the induction of dyskinesias while improving motor performance. (C) 2001 Movement Disorder Society.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/04/20 alle ore 05:56:11